OBJECTIVES: This study tested whether immunosuppression with mycophenolate mofetil (MMF) inhibits atherosclerosis development in apolipoprotein-E-deficient (Apoe(-/-)) mice and investigated the mechanism. BACKGROUND: Chronic vascular inflammation involving both innate and adaptive immunity is central in the development of atherosclerosis, but immunosuppressive treatment is not uniformly beneficial. The immunosuppressive MMF targets lymphocyte proliferation by inhibiting inosine-monophosphate dehydrogenase. METHODS: Young and aged Apoe(-/-) mice were treated with 30 mg/kg daily MMF during 12 and 3 weeks of a high-fat diet, respectively. Aortic lesion size and composition was investigated by histology and flow cytometry; soluble inflammatory mediators were investigated by enzyme-linked immunosorbent assay. RESULTS: Macroscopic and histologic aortic atherosclerotic lesions were significantly decreased in both MMF-treated groups. While systemic immunoglobulin G directed against low-density lipoproteins was not significantly altered, the T-cell cytokine interleukin (IL)-17 was significantly reduced in plasma of MMF-treated mice and supernatants from their aortas after T-cell stimulation. The MMF treatment decreased aortic αβ T-cell receptor(+) lymphocyte proliferation and cell numbers. Also, aortic contents of CD11b(+)CD11c(+) cells and their proliferation were reduced in MMF-treated Apoe(-/-) mice. The IL-17 supplementation restored the number of proliferating aortic CD11b(+)CD11c(+) cells in MMF-treated mice. The IL-17 receptor A was highly expressed on circulating monocytes that are macrophage progenitors. Genetic deletion of IL-17 receptor A or IL-17A reduced inflammatory peritoneal CD11b(+)CD11c(+) macrophage accumulation. CONCLUSIONS: The lymphocyte-directed immunosuppressant MMF that curbs IL-17 production was a successful antiatherosclerotic treatment. Our data delineate a role for IL-17 in CD11b(+)CD11c(+) cell accumulation. 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
OBJECTIVES: This study tested whether immunosuppression with mycophenolate mofetil (MMF) inhibits atherosclerosis development in apolipoprotein-E-deficient (Apoe(-/-)) mice and investigated the mechanism. BACKGROUND:Chronic vascular inflammation involving both innate and adaptive immunity is central in the development of atherosclerosis, but immunosuppressive treatment is not uniformly beneficial. The immunosuppressive MMF targets lymphocyte proliferation by inhibiting inosine-monophosphate dehydrogenase. METHODS: Young and aged Apoe(-/-) mice were treated with 30 mg/kg daily MMF during 12 and 3 weeks of a high-fat diet, respectively. Aortic lesion size and composition was investigated by histology and flow cytometry; soluble inflammatory mediators were investigated by enzyme-linked immunosorbent assay. RESULTS: Macroscopic and histologic aortic atherosclerotic lesions were significantly decreased in both MMF-treated groups. While systemic immunoglobulin G directed against low-density lipoproteins was not significantly altered, the T-cell cytokine interleukin (IL)-17 was significantly reduced in plasma of MMF-treated mice and supernatants from their aortas after T-cell stimulation. The MMF treatment decreased aortic αβ T-cell receptor(+) lymphocyte proliferation and cell numbers. Also, aortic contents of CD11b(+)CD11c(+) cells and their proliferation were reduced in MMF-treated Apoe(-/-) mice. The IL-17 supplementation restored the number of proliferating aortic CD11b(+)CD11c(+) cells in MMF-treated mice. The IL-17 receptor A was highly expressed on circulating monocytes that are macrophage progenitors. Genetic deletion of IL-17 receptor A or IL-17A reduced inflammatory peritoneal CD11b(+)CD11c(+) macrophage accumulation. CONCLUSIONS: The lymphocyte-directed immunosuppressant MMF that curbs IL-17 production was a successful antiatherosclerotic treatment. Our data delineate a role for IL-17 in CD11b(+)CD11c(+) cell accumulation. 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Authors: Sander I van Leuven; John J P Kastelein; Anthony C Allison; Michael R Hayden; Erik S G Stroes Journal: Cardiovasc Res Date: 2005-11-10 Impact factor: 10.787
Authors: J Kobashigawa; L Miller; D Renlund; R Mentzer; E Alderman; R Bourge; M Costanzo; H Eisen; G Dureau; R Ratkovec; M Hummel; D Ipe; J Johnson; A Keogh; R Mamelok; D Mancini; F Smart; H Valantine Journal: Transplantation Date: 1998-08-27 Impact factor: 4.939
Authors: Hafid Ait-Oufella; Benoît L Salomon; Stéphane Potteaux; Anna-Karin L Robertson; Pierre Gourdy; Joffrey Zoll; Régine Merval; Bruno Esposito; José L Cohen; Sylvain Fisson; Richard A Flavell; Göran K Hansson; David Klatzmann; Alain Tedgui; Ziad Mallat Journal: Nat Med Date: 2006-02-05 Impact factor: 53.440
Authors: Elena Galkina; Alexandra Kadl; John Sanders; Danielle Varughese; Ian J Sarembock; Klaus Ley Journal: J Exp Med Date: 2006-05-08 Impact factor: 14.307
Authors: Shuwang Ge; Barbara Hertel; Ekaterina K Koltsova; Inga Sörensen-Zender; Jan T Kielstein; Klaus Ley; Hermann Haller; Sibylle von Vietinghoff Journal: Circ Res Date: 2013-08-01 Impact factor: 17.367
Authors: Qunzhou Zhang; Ikiru Atsuta; Shiyu Liu; Chider Chen; Shihong Shi; Songtao Shi; Anh D Le Journal: Clin Cancer Res Date: 2013-04-24 Impact factor: 12.531
Authors: Ekaterina K Koltsova; Gisen Kim; Kathleen M Lloyd; Christiaan J M Saris; Sibylle von Vietinghoff; Mitchell Kronenberg; Klaus Ley Journal: Circ Res Date: 2012-08-27 Impact factor: 17.367
Authors: Shuwang Ge; Barbara Hertel; Nathan Susnik; Song Rong; Anna M Dittrich; Roland Schmitt; Hermann Haller; Sibylle von Vietinghoff Journal: PLoS One Date: 2014-01-15 Impact factor: 3.240